Return to Home [X]

Exciting News: Introducing the New Essential Evidence Plus!

We are thrilled to announce that a brand-new version of Essential Evidence Plus is on its way! Mark your calendars for the launch date, September 11th, as we are introducing a modern, mobile-first application that will revolutionize your experience. With this update, accessing our valuable content will be easier and more convenient than ever before.

What to Expect from the New Essential Evidence Plus:

  1. Modern Mobile-First Experience: Our new application has been meticulously designed with a mobile-first approach. No matter what device you're using, whether it's a smartphone, tablet, or desktop, you'll enjoy a seamless and intuitive user experience.
  2. Enhanced Accessibility: We understand the importance of accessing content from anywhere, at any time. The new Essential Evidence Plus will provide you with the flexibility to explore our extensive collection of evidence-based resources on the go, making it easier to stay up to date with the latest medical knowledge and interactive tools.
  3. Improved User Interface: We have revamped our user interface to ensure effortless navigation and a visually appealing experience. Finding the information, you need will be quicker and more intuitive, saving you valuable time and effort.

Essential Evidence Plus will be available to users during this transition. However, please note that ability to create new trial and individual subscriptions will not be available from September 8th to September 11th 7:00 AM EST. During this period, we will be working diligently to transfer our existing system to the upgraded platform, ensuring a seamless transition for all users.

We apologize for any inconvenience caused by this temporary interruption. Rest assured, our team is committed to bringing you a superior user experience, and we appreciate your patience and understanding during this time.

Stay Tuned for the New Essential Evidence Plus!

We are counting down the days until September 11th when the new Essential Evidence Plus will be available for you to explore. Get ready to unlock a wealth of evidence-based resources that empower you in your medical decision-making process.

Thank you for your continued support, and we look forward to delivering an exceptional experience with the all-new Essential Evidence Plus!

Essential Evidence Plus

Browse Databases and Tools

Sort by Show per page
  • Valerian for anxiety disorders
    Cochrane Systematic Reviews, 5-Nov-2008
  • Validation therapy for dementia
    Cochrane Systematic Reviews, 6-Nov-2008
  • Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults
    Cochrane Systematic Reviews, 24-Jun-2013
  • Valproate for acute mania
    Cochrane Systematic Reviews, 7-Oct-2019
  • Valproate for schizophrenia
    Cochrane Systematic Reviews, 24-Nov-2016
  • Valproate preparations for agitation in dementia
    Cochrane Systematic Reviews, 5-Oct-2018
  • Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults
    Cochrane Systematic Reviews, 5-Oct-2011
  • Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder
    Cochrane Systematic Reviews, 16-Oct-2013
  • Vancomycin for prophylaxis against sepsis in preterm neonates
    Cochrane Systematic Reviews, 24-Jan-2000
  • Vapocoolants (cold spray) for pain treatment during intravenous cannulation
    Cochrane Systematic Reviews, 26-Apr-2016
  • Vascular access specialist teams for device insertion and prevention of failure
    Cochrane Systematic Reviews, 20-Mar-2018
  • Vascular closure devices for femoral arterial puncture site haemostasis
    Cochrane Systematic Reviews, 26-Feb-2016
  • Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer
    Cochrane Systematic Reviews, 4-Mar-2021
  • Vascular occlusion for elective liver resections
    Cochrane Systematic Reviews, 21-Jan-2009
  • Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer
    Cochrane Systematic Reviews, 29-May-2012
  • Vasectomy occlusion techniques for male sterilization
    Cochrane Systematic Reviews, 30-Mar-2014
  • Vasoactive drugs for acute stroke
    Cochrane Systematic Reviews, 7-Jul-2010
  • Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss
    Cochrane Systematic Reviews, 7-Oct-2009
  • Vasodilators for primary Raynaud's phenomenon
    Cochrane Systematic Reviews, 17-May-2021
  • Vasodilators for women undergoing fertility treatment
    Cochrane Systematic Reviews, 11-Oct-2018

Login or Subscribe


Not Yet a Subscriber?

Doctor with handheld

We offer subscriptions for individuals and institutions

To find out about all the benefits of a year-long subscription to Essential Evidence Plus, click the button below!

Learn More